Table 1.

Main characteristics of the eligible studies included in the meta-analysis

Author	Year	Country	Patients number	Age (years)	FIGO Stage	Tumor Grade	Tumor type	cut-off value (× 109/L)	Incidence of thrombocytosis (%)	Follow-up time (month)	Primary Outcome	NOS
Abu-Zaid [24]	2017	Saudi Arabia	162	59	I–IV	1–3	endometrioid	400	8.6	NR	OS, DFS	6
Andersen [27]	2017	Denmark	218	18–80	I–IV	1–3	mixed	400	11.5	NR	OS, DSS	6
Njølstad [28]	2013	Norway	512	28–93	I–IV	1–3	mixed	390	12.3	55(0–97)	DFS	6
Kizer [22]	2015	USA	318	62	I–IV	1–3	mixed	400	16.7	NR	DFS, DSS	6
Nakamura [23]	2016	Japan	108	60	I–IV	1–3	mixed	350	11.02	NR	OS, PFS	6
Takahashi [26]	2017	Japan	508	58	I–IV	1–3	mixed	400	7	NR	OS	6
Heng [20]	2014	Thailand	238	28–88	I–IV	1–3	mixed	400	18.1	59.6(1–98)	OS, DFS	7
Matsuo [19]	2013	USA	516	52	I–IV	1–3	mixed	400	15.1	43.7	OS, DFS	8
Gorelick [18]	2009	USA	77	65	I–IV	1–3	mixed	400	18.2	NR	OS	6
Lerner [17]	2007	USA	68	NR	III-IV	NR	serous	400	12	NR	OS	6
Moeini [25]	2017	USA	714	53.1	I–IV	1–3	mixed	400	24.8	28.8	OS, DFS	8

Abbreviations: NOS Newcastle Ottawa Scale, NR not reported, FIGO International Federation of Gynecology and Obstetrics, OS overall survival, PFS progression-free survival, DFS disease-free survival, DSS disease-specific survival